Assessing Emerging Infectious Threats to Blood Safety for the Blood Disorders Community

American Journal of Preventive Medicine

Volumn 38, Issue 4 SUPPL., 2010, Pages

  Trimble, Sean R ^a   Parker, Christopher S ^a   Grant, Althea M ^a   Soucie, J Michael ^a   Reyes, Nimia ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BABESIA; BACTERIAL TRANSMISSION; BLOOD DISEASE; BLOOD DONOR; BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; NONHUMAN; PARASITE TRANSMISSION; PARVOVIRUS; PREVENTIVE MEDICINE; REVIEW; RISK REDUCTION; SCREENING TEST; TRYPANOSOMA CRUZI; UNITED STATES; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; HEMATOLOGIC DISEASES; HUMANS;

EID: 77949433489     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2009.12.019     Document Type: Review

References (53)

1. Ceccherini-Nelli L., Filipponi F., Mosca F., and Campa M. The risk of contracting and infectious disease from blood transfusion. Transplant Proc 36 3 (2004) 680-682
2. Allain J.P., Stramer S.L., Carneiro-Proietti A.B., et al. Transfusion-transmitted infectious diseases. Biologicals 37 2 (2009) 71-77
3. Freireich E.J., Schmidt P.J., Schneidermann M.A., and Frei III E. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N Engl J Med 260 (1959) 6-11
4. Beeson P.B. Jaundice occurring one to four months after transfusion of blood or plasma. JAMA 121 (1943) 1332-1337
5. Pittman M. A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med 42 2 (1953) 273-288
6. Wagner S. Transfusion-related bacterial sepsis. Curr Opin Hematol 4 6 (1997) 464-469
7. Kuehnert M.J., Roth V.R., Haley N.R., et al. Transfusion-transmitted bacterial infection in the U.S., 1998 through 2000. Transfusion 41 12 (2001) 1493-1499
8. Goodnough L.T., Shander A., and Brecher M.E. Transfusion medicine: looking to the future. Lancet 361 9352 (2003) 161-169
9. Richards C., Kolins J., and Trindade C.D. Autologous transfusion-transmitted Yersinia enterocolitica. JAMA 268 12 (1992) 154-2
10. Wagner S.J. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 86 3 (2004) 157-163
11. Wagner S.J., Friedman L.I., and Dod R.Y. Clin Microbiol Rev 7 (1994) 290
12. Dodd R.Y. Adverse consequences of blood transfusion: quantitative risk estimates. Blood supply: risks, perceptions, and prospects for the future (1994), American Association of Blood Banks, Bethesda MD
13. Stevens C.E., Silbert J.A., Miller D.R., Dienstag J.L., Purcell R.H., and Szmuness W. Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study. Transfusion 18 3 (1978) 356-360
14. Soucie J.M., Robertson B.H., Bell B.P., McCaustland K.A., and Evatt B.L. Hepatitis A virus infections associated with clotting factor concentrate in the U.S. Transfusion 38 6 (1998) 573-579
15. Mannucci P.M., Gdovin S., Gringeri A., et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 120 1 (1994) 1-7
16. Johnson Z., Thornton L., Tobin A., et al. An outbreak of hepatitis A among Irish haemophiliacs. Int J Epidemiol 24 4 (1995) 821-828
17. Brackmann H.H., Oldenburg J., Eis-Hubinger A.M., Gerritzen A., Hammerstein U., and Hanfland P. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 67 1S (1994) S3-S7
18. Peerlinck K., and Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet 341 8838 (1993) 179
19. Kedda M.A., Kew M.C., Cohn R.J., et al. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology 22 5 (1995) 1363-1367
20. Fiore A.E., Wasley A., and Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-7 (2006) 1-23
21. Candotti D., and Allain J.P. Transfusion-transmitted hepatitis B virus infection. J Hepatol 51 4 (2009) 798-809
22. Goodnough L.T. Risks of blood transfusion. Crit Care Med 31 12S (2003) S678-S686
23. Dodd R.Y., Notari E.P., and Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42 8 (2002) 975-979
24. AuBuchon J.P., Birkmeyer J.D., and Busch M.P. Safety of the blood supply in the U.S.: opportunities and controversies. Ann Intern Med 127 10 (1997) 904-909
25. Busch M.P., Korelitz J.J., Kleinman S.H., Lee S.R., AuBuchon J.P., and Schreiber G.B. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 35 11 (1995) 903-910
26. Matsubayashi K., Nagaoka Y., Sakata H., et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 44 6 (2004) 934-940
27. Boxall E., Herborn A., Kochethu G., et al. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med 16 2 (2006) 79-83
28. Mitsui T., Tsukamoto Y., Yamazaki C., et al. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol 74 4 (2004) 563-572
29. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 12 7S (1990) S701-S710
30. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86 9 (1995) 3598-3603
31. Landaw E.M., Kanter M., and Petz L.D. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood 87 (1996) 4910
32. West Nile virus activity-U.S., October 10-16, 2002, and update on West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep 51 41 (2002) 929-931
33. Pealer L.N., Marfin A.A., Petersen L.R., et al. Transmission of West Nile virus through blood transfusion in the U.S. in 2002. N Engl J Med 349 13 (2003) 1236-1245
34. Stramer S.L., Fang C.T., Foster G.A., Wagner A.G., Brodsky J.P., and Dodd R.Y. West Nile virus among blood donors in the U.S., 2003 and 2004. N Engl J Med 353 5 (2005) 451-459
35. Busch M.P., Caglioti S., Robertson E.F., et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 353 5 (2005) 460-467
36. Brown K.E., and Young N.S. Human parvovirus B19 infections in infants and children. Advances in Pediatric Infectious Diseases Vol 13 (1998), Mosby-Year Book, Inc
37. Tavil B., Sanal O., Turul T., Yel L., Gurgey A., and Gumruk F. Parvovirus B19-induced persistent pure red cell aplasia in a child with T-cell immunodeficiency. Pediatr Hematol Oncol 26 2 (2009) 63-68
38. Nocton J.J., Miller L.C., Tucker L.B., and Schaller J.G. Human parvovirus B19-associated arthritis in children. J Pediatr 122 (1993) 186-190
39. Murai C., Munakata Y., Takahashi Y., et al. Rheumatoid arthritis after human parvovirus B19 infection. (letter). Ann Rheum Dis 58 (1999) 130-132
40. Altschuler E.L. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 354 (1999) 1026-1027
41. Takahashi Y., Murai C., Shibata S., et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci 95 (1998) 8227-8232
42. Kishore J., Misra R., Gupta D., and Ayyagari A. Raised IgM antibodies to parvovirus B19 in juvenile rheumatoid arthritis. Indian J Med Res 107 (1998) 15-18
43. Anderson J.A.M., Dennis R., and Ludlam C.A. Seroconversion to parvovirus B19 following a course of treatment with plasma-derived factor VIII. Haemophilia 6 (2000) 356
44. Azzi A., Morfini M., and Mannucci P.M. The transfusion-associated transmission of parvovirus B19. Transfusion Med Rev 13 (1999) 194-204
45. Santagostino E., Mannucci P.M., Gringeri A., et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 37 (1997) 517-522
46. Bhattacharyya S.P., Tan D., Quo Z.P., Mason B.L., Jong J.J., and Vu M.W. Presence of human parvovirus B19 DNA in factor VIII concentrates: effects of viral clearance and product purification procedures. Haemophilia 6 (2000) 353
47. Leiby D.A., Herron Jr. R.M., Read E.J., Lenes B.A., and Stumpf R.J. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42 5 (2002) 549-555
48. Young C., Losikoff P., Chawla A., Glasser L., and Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 47 3 (2007) 540-544
49. Gerber M.A., Shapiro E.D., Krause P.J., Cable R.G., Badon S.J., and Ryan R.W. The risk of acquiring Lyme disease or Babesiosis from a blood transfusion. J Infect Dis 170 1 (1994) 231-234
50. Cable R.G., Badon S., Trouern-Trend J., et al. Evidence for transmission of Babesia microti from Connecticut blood donors to recipients. Transfusion 41 (2001) S12-S13
51. Health Protection Agency. Variant CJD and plasma products. Press Release (2009). www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733818681?p=1225960597236
52. Holada K., Vostal J.G., Theisen P.W., MacAuley C., Gregori L., and Rohwer R.G. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 76 9 (2002) 4649-4650
53. Cervenakova L., Yakovleva O., McKenzie C., et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43 12 (2003) 1687-1694